Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men
about
Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazolePosaconazole: an oral triazole with an extended spectrum of activityAspergillus infections in transplant recipients.Posaconazole as salvage therapy for zygomycosis.Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Human pharmacogenomic variations and their implications for antifungal efficacy.Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature.Emerging azole antifungals.Posaconazole: clinical pharmacology and potential for management of fungal infections.Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.Posaconazole: a new broad-spectrum antifungal agent.Posaconazole in the management of refractory invasive fungal infections.Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.Antifungal agents--clinical pharmacokinetics and drug interactions.Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.New and investigational triazole agents for the treatment of invasive fungal infections.Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.New generation azole antifungals in clinical investigation.Management of drug and food interactions with azole antifungal agents in transplant recipients.Use of posaconazole in the treatment of invasive fungal infections.Posaconazole: when and how? The clinician's view.Clinically significant drug interactions with antacids: an update.Triazole antifungal agents in invasive fungal infections: a comparative review.Safety of posaconazole.Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole.Treatment of Disseminated Aspergillosis with Posaconazole in 10 Dogs.Posaconazole (Noxafil): a new triazole antifungal agent.Posaconazole: An Update of Its Clinical Use.Advances in synthetic approach to and antifungal activity of triazoles.Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview.A routine method for the quantification of the novel antimycotic drug posaconazole in plasma using liquid chromatography-tandem mass spectrometry.Development and validation of a high-performance liquid chromatography assay for posaconazole utilizing solid-phase extraction.Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
P2860
Q26782472-207483D3-A0E4-4C87-A9E7-C9880BCB792BQ28291282-F2740481-6330-4942-8147-464E6A26637CQ33719294-BF4BDC14-600D-4097-B84B-38E5C64AA6CAQ34301611-CF436BB2-2BB0-4D74-916B-49F4D9BC07B5Q34648517-818D7481-572C-4689-A340-0E2215BC7C0AQ34680655-EC104600-CDB9-4A5B-B393-327E304516B0Q34701325-E4028B97-33F5-4E79-95A6-A443E64182B9Q35026481-37E0AC76-1266-40B5-BD6C-41F08D47AF2DQ35070838-6F70293F-34C0-43E9-A04E-20D6E93A49A8Q35635971-A9B0165D-6D33-494F-AD51-DACAA4D49B46Q35860057-B4CAA729-B7B6-4DD5-95C6-259E8F69AE53Q35959476-B37802B1-B71B-4ADE-996B-5B744176C291Q36066009-8DAD069B-57D9-4313-91D8-C631C2E81A44Q36233491-9E2BCD94-9C20-4858-8F7B-A472FCD9DEF0Q36491819-A29CDA83-CA03-4EC0-BE1C-735425BA4C55Q36828159-DCE0ADE9-4375-45A9-BA43-CF521F6AA56BQ37052755-41E8D7FF-8630-4C05-8D03-8490A1474E18Q37055215-F8407AFB-3F82-4B6A-9398-E82925524148Q37115829-A53FA7F9-9433-4774-9D16-96CCCAC3012CQ37159568-CABB72BD-E7BE-43CC-A355-D412CE12A150Q37203849-1B6E823A-C8E2-40FB-8054-6A45D26A49C4Q37364295-CE2937A7-A550-4BE4-8DEE-BDCC2B163F45Q37404840-3E0569CF-10F3-4535-8D86-874727FABB72Q37579222-CCAAFAD1-1E97-47B6-BFFA-59201A3BE729Q37775009-4AA24C83-B536-4CFF-908B-339564641DB7Q37810083-94595B41-49C7-424F-93CD-CF0C1539B9C7Q37901534-64BCD040-33CB-4140-A5C8-028A9E75F3DBQ37937722-5315963D-14BE-4351-B6BB-5A961AC302A6Q37964703-12D63697-BCED-4306-B5AC-10C6100B367BQ38077591-0787C3C3-CF04-4352-B101-1A27A92042FCQ38341595-03321A46-B632-4994-B6CB-37FFEB098E80Q40323166-3B944E3B-D2F4-4C17-857E-B2CD5DEB4BDCQ40452729-2BA8AC2B-3604-4642-AC23-82949962B5BFQ42144246-9CDA1ADB-6515-4990-A46A-7DA3860AAC12Q42206400-3CF1759F-E532-481E-8B9D-4552447C01B6Q42413286-CA651D20-68F4-4B5C-BAC6-236A7CAA5F4DQ45172325-F97D09E3-508B-4B68-8E9B-F340DFB54FE8Q46273412-484FAF13-8C32-4E1C-AB9E-7C322EC57D0FQ46341880-7B61025A-B7EF-4965-A104-3BED644DA713
P2860
Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Pharmacokinetics of posaconazo ...... ting or nonfasting healthy men
@ast
Pharmacokinetics of posaconazo ...... ting or nonfasting healthy men
@en
type
label
Pharmacokinetics of posaconazo ...... ting or nonfasting healthy men
@ast
Pharmacokinetics of posaconazo ...... ting or nonfasting healthy men
@en
prefLabel
Pharmacokinetics of posaconazo ...... ting or nonfasting healthy men
@ast
Pharmacokinetics of posaconazo ...... ting or nonfasting healthy men
@en
P2093
P2860
P1476
Pharmacokinetics of posaconazo ...... ting or nonfasting healthy men
@en
P2093
Elaine Radwanski
Josephine Lim
Mark Laughlin
Rachel Courtney
P2860
P304
P356
10.1128/AAC.48.3.804-808.2004
P407
P577
2004-03-01T00:00:00Z